-
公开(公告)号：EP2895866B1
公开(公告)日：2018-05-30
申请号：EP13713175.1
申请日：2013-03-28
发明人： BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
-
公开(公告)号：EP3279665B1
公开(公告)日：2020-07-08
申请号：EP16182825.6
申请日：2016-08-04
申请人： Roche Diagnostics GmbH , F. Hoffmann-La Roche AG , Universiteit Maastricht , Academisch Ziekenhuis Maastricht
发明人： KARL, Johann , KASTNER, Peter , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZIEGLER, Andre , DIETRICH, Manuel , SCHOTTEN, Uli
IPC分类号： G01N33/68
-
3.发明公开
公开(公告)号：EP3472622A1
公开(公告)日：2019-04-24
申请号：EP17733406.7
申请日：2017-06-19
发明人： ANDRES, Herbert , BLOCK, Dirk , KARL, Johann , KASTNER, Peter , WIENHUES-THELEN, Ursula-Henrike , LATINI, Roberto , MASSON, Serge , ZIEGLER, André , KAISER, Edelgard , PALME, Stefan , THOMAS, Markus , BARLERA, Simona
IPC分类号： G01N33/68
摘要： The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：EP4222499A1
公开(公告)日：2023-08-09
申请号：EP21783295.5
申请日：2021-09-30
-
公开(公告)号：EP3213085B1
公开(公告)日：2018-12-12
申请号：EP15790874.0
申请日：2015-10-28
发明人： LATINI, Roberto , MASSON, Serge , BLOCK, Dirk , ZAUGG, Christian , DIETERLE, Thomas , KAISER, Edelgard , KARL, Johann , ROLNY, Vinzent , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2333/4712 , G01N2333/4745 , G01N2333/475 , G01N2333/495 , G01N2333/50 , G01N2333/515 , G01N2333/58 , G01N2333/70525 , G01N2800/325
摘要： The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
-
6.发明授权
公开(公告)号：EP3472622B1
公开(公告)日：2020-08-05
申请号：EP17733406.7
申请日：2017-06-19
发明人： ANDRES, Herbert , BLOCK, Dirk , KARL, Johann , KASTNER, Peter , WIENHUES-THELEN, Ursula-Henrike , LATINI, Roberto , MASSON, Serge , ZIEGLER, André , KAISER, Edelgard , PALME, Stefan , THOMAS, Markus , BARLERA, Simona
IPC分类号： G01N33/68
-
公开(公告)号：EP2917736B1
公开(公告)日：2019-12-25
申请号：EP13789010.9
申请日：2013-11-11
发明人： BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
-
公开(公告)号：EP3213085A1
公开(公告)日：2017-09-06
申请号：EP15790874.0
申请日：2015-10-28
发明人： LATINI, Roberto , MASSON, Serge , BLOCK, Dirk , ZAUGG, Christian , DIETERLE, Thomas , KAISER, Edelgard , KARL, Johann , ROLNY, Vinzent , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2333/4712 , G01N2333/4745 , G01N2333/475 , G01N2333/495 , G01N2333/50 , G01N2333/515 , G01N2333/58 , G01N2333/70525 , G01N2800/325
摘要： The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
摘要翻译： 本发明涉及用于预测由于慢性心力衰竭和/或死亡而快速进展为慢性心力衰竭和/或住院的对象风险的方法。 该方法基于至少一种选自BNP型肽，IGFBP7（IGF结合蛋白7），心脏肌钙蛋白，可溶性ST2（sST2），FGF-23（成纤维细胞生长因子23 ）和生长分化因子15（GDF-15）。 该方法还可以包括评估（i）异常中壁分数缩短或（ii）左心室肥大的存在或不存在。 本发明进一步设想的是适合于执行本发明的设备。
-
-
公开(公告)号：EP3494397A1
公开(公告)日：2019-06-12
申请号：EP17745763.7
申请日：2017-08-04
发明人： KARL, Johann , KASTNER, Peter , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZIEGLER, André , DIETRICH, Manuel , SCHOTTEN, Ulrich , ROLNY, Vinzent
IPC分类号： G01N33/68
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.015 秒)
